








UKRTN committee bios



<p>Nicola Anderson</p>		<p>Nicola is employed by University Hospitals Birmingham NHS Foundation Trust as a Senior Research Nurse specialising in renal research. In 1992 Nicola completed a Law degree (BA Hons Cantab) and trained as a Solicitor before deciding that her career interests lay elsewhere and qualified as a Nurse in 1999. She has worked within the field of clinical research since 2003, in both clinical and teaching roles. She has broad experience of study management including the coordination of multi-centre CTIMP and device studies. She completed a MSc in Healthcare Law and Ethics in 2008 and she is currently enrolled on a PhD programme at the Centre for Patient Reported Outcomes Research, Institute of Applied Health Research, University of Birmingham exploring the use of Patient Reported Outcome Measures (PROMs) in the routine care of patients being treated with haemodialysis.</p>
<p>Colin Baigent</p>		<p>Professor Colin Baigent is Director of the MRC Population Health Research Unit and Deputy Director of the Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU) at the University of Oxford, where he is Professor of Epidemiology. He has led some of the world's largest collaborative meta-analyses of randomized trials, typically with individual participant data, resulting in landmark papers that have helped determine, for example, the effects of statins and aspirin in different types of people. He led the Study of Heart and Renal Protection (SHARP), the largest ever randomized trial in patients with moderate-to-severe chronic kidney disease (CKD), recruiting 9438 patients in nearly 400 hospitals in 18 countries. His group is now coordinating the EMPA KIDNEY trial, a trial comparing empagliflozin versus placebo in 5000 patients with CKD, which is designed to assess the effects of empagliflozin on progression to ESRD or cardiovascular death.</p>




Simon Bond		<p>Simon Bond leads the statistical team within Cambridge Clinical Trials Unit, and is a visiting worker at the MRC Biostatistics Unit. The portfolio of trials covers numerous medical specialities and all phases, with an emphasis on adaptive early phase trials. Simon leads the Early Phase Trials section within the NIHR Statistics Group, and serves as a member of the board for the Efficacy and Mechanism Evaluation NIHR programme.</p>
Fergus Caskey		<p>Dr Fergus Caskey is Consultant Nephrologist in Bristol and Medical Director of the UK Renal Registry. Interested in using mixed methods alongside registry data to study inequalities in access to treatment and outcomes in kidney disease and to optimise trial design.</p>
Martin Christian		<p>Martin Christian has worked as an NHS consultant paediatric nephrologist in Nottingham since 2004 after training at Great Ormond Street and Guy's Hospitals. He is currently the network lead for a large clinical network with shared care clinics in 20 local centres outside Nottingham, and leads a twice-yearly education meeting and a patient-professional website.</p> <p>His clinical and research interests are in nephrotic syndrome and transplantation, mainly through participation in multi-centre studies. In 2018, he became Chief Investigator for PREDNOS 2, a large multi-centre study of childhood nephrotic syndrome. He has been the UK Chief Investigator for an industry-led, international multi-centre paediatric transplantation immunosuppression study (CRADLE) and he is also</p>


		currently co-leading a project to harmonise immunosuppression regimes for UK paediatric renal transplant centres. Martin has been a council member of the European Society for Paediatric Nephrology since 2018.
Claire Corps		Claire is a Doctor of Research working as a Scientist in the NHS with an interest in renal disease and transplantation. Her education includes her PhD in Energy Kinetics in Preserved Livers which she studied for in Leeds and a M.Sc. in Immunology and Immunogenetics at the University of Manchester, preceded by her BSc (Hons) in Microbiology in Leeds. Claire's interest and knowledge in renal disease is driven by her unique perspective having had renal failure since childhood and following haemodialysis has been the recipient of both kidney and liver transplants. She is Co-Chair of the Measurement Workstream in the Transforming Participation in CKD Programme, an active Committee Member of both West Riding Kidney Patients Association and the UK Renal Registry Patient Council.
Simon Davies		Simon Davies is Professor of Nephrology and Dialysis Medicine at Keele University and a Consultant Nephrologist at the University Hospital of North Staffordshire. His research focusses on Peritoneal Dialysis, in particular peritoneal membrane function, and the assessment and management of fluid status in dialysis patients of both modalities. He instigated several national and international cohort studies, including EAPOS, PDOPPS, the Global Fluid Study, PD-CRAFT, and trials of icodextrin and bioimpedance technologies. Currently his research is funded by the NIH [Bio-PD], NIHR HTA [BISTRO trial] and KRUK [UK-PDOPPS] and EU Horizon 2020 [IMPROVE-PD]. He is a member of the Keele CTU Leadership Group and the West Midlands Research Design Service. He is Associate Editor of Peritoneal Dialysis International, chairs the International Society of Nephrology Dialysis Work Group and is past president of the International Society of Nephrology.
Mary Dutton		Mary Dutton is Lead Nurse for Renal Research at University Hospital Birmingham NHS Foundation Trust and has worked in this role since 2006. Mary is a RGN qualified nurse (JBCNS Renal Nursing 1982) with 30 years nephrology nursing experience and she completed a MSc in



		<p>Nursing and Healthcare at Edinburgh in 1991. She has a broad range of trials management experience, including involvement with study design and protocol development, grant application, co-ordination of multicentre studies. She is has previously been Chair RCN Dialysis and Transplant Nursing Forum and since 2016 is a Member of the Centre for Patient Reported Outcomes Research, Institute of Applied Health Research, University of Birmingham</p>
Charles Ferro		<p>Professor Ferro obtained degrees in Biochemistry and Medicine from the University of Edinburgh graduating in 1991. He trained in renal medicine in Edinburgh, Glasgow, Truro and Bristol. He has been a consultant nephrologist at the University Hospitals Birmingham with senior academic positions at the University of Birmingham since 2002. His clinical and research interests include the aetiology and treatment of cardiovascular disease in patients with chronic kidney disease. Currently Professor Ferro is the Principal Investigator for several international and national clinical studies funded mainly by grants from the National Institute for Health Research, the British Heart Foundation and Kidney Research UK. In 2015 Professor Ferro was elected by his peers to serve as a Board Member on the European Renal and Cardiovascular Medicine Working Group of the European Renal Association and in 2017 he was elected vice-chairman. Professor Ferro is a distinguished Fellow of the European Renal Association.</p>
Richard Haynes		<p>Richard Haynes did his pre-clinical medical studies in Cambridge before moving to Oxford for his clinical studies and qualified in 2000. He came to CTSU for a period of “out of programme” research in 2006 to work on the HPS2-THRIVE trial with Prof Jane Armitage. He completed his training in renal medicine in 2011 and was appointed as an honorary consultant at the Oxford Kidney Unit. Shortly after that he was appointed to the MRC Programme Leader track and he is now Programme Leader in the MRC Population Health Research Unit for the programme in Randomised Trials in Cardiovascular and Metabolic Disease</p>

<p>Will Herrington</p>		<p>Will Herrington studied medicine at University of Cambridge and University College London (1997-2003) and was appointed an Honorary Consultant Nephrologist at Oxford Kidney Unit in 2014. He joined the Renal Studies Group at Clinical Trial Service Unit and Epidemiological Studies Unit in 2010 and worked on SHARP, 3C and UK-HARP3. He is also on the adjudication committees for REVEAL and ACST-2. His current research also focuses on understanding the key determinants of developing kidney disease and cardiovascular disease through use of large blood-based cohorts and streamlined randomized trial. He was Scientific Co-ordinator for the 2106 KDIGO Controversies Conference on Challenges in the Conduct of Clinical Trials in Nephrology and was a project leader for the recent Clinical Trial Transformation Initiative's "Developing Novel Endpoints Generated by Mobile Technology for Use in Clinical Trials" Working Group. He is currently the Deputy Chair of the UKRTN.</p>
<p>Thomas Hiemstra</p>		<p>Thomas Hiemstra is a Lecturer in Trials at the University of Cambridge, Trials Methodologist with the Cambridge Clinical Trials Unit, and Honorary Consultant Nephrologist at Addenbrooke's Hospital. He is a steering board member of ISN-Advancing Clinical Trials (ACT) (https://www.theisn.org/research/isn-act), is Deputy chair of the International Clinical Trials Center Network (https://www.icn-connect.org), and leads a portfolio of phase I to IV trials. He has a specific interest in efficient trial design and has served as UKRTN chair since 2016</p>
<p>David Jayne</p>		<p>David Jayne is Professor of Clinical Autoimmunity at the School of Clinical Medicine, University of Cambridge, UK. After training at Cambridge University and St Thomas Hospital, London, he received postgraduate training at several London hospitals and was a research fellow at Gonville and Caius College, Cambridge and Harvard University. He is a fellow of the Royal Colleges of Physicians of London and Edinburgh, and the Academy of Medical Sciences. He is a certified nephrologist and an Honorary Consultant Physician at Addenbrooke's Hospital, Cambridge UK. His research group conducts clinical trials and</p>

		<p>biomarker studies in vasculitis and lupus. He is the Director of the Vasculitis and Lupus Clinic and President of the European Vasculitis Society.</p>
Phil Kalra		<p>Professor Philip Kalra is Professor of Nephrology at Salford Royal NHS Foundation Trust and the University of Manchester. He is lead of the renal research team at Salford with research interests in renovascular disease, cardiovascular disease in CKD, CKD epidemiology and biomarkers of progression. He is the current Academic Vice President of the Renal Association (2016-19) and was chair of the National Renal speciality group of the NIHR CRN clinical trials network 2010-18, and recent chair of the UK Kidney Research Consortium (2016-18). He has contributed to the development of several large UK clinical trials in nephrology and cardiology and has played a role in amalgamating Cardio-Renal education and research within the UK.</p>
Patrick Mark		<p>Paddy Mark is a Clinical Reader and Honorary Consultant Nephrologist at the Glasgow Renal and Transplant Unit based at the Queen Elizabeth University Hospital Glasgow. He was appointed as Clinical Senior Lecturer in 2011 following clinical training in Medicine and Nephrology combined with a Clinical Lecturer post between 2006-2011. He leads the United Kingdom Cardio-Renal Clinical Study Group, as part of the United Kingdom Kidney Research Consortium. He is the Chief Scientist Office Scotland Clinical Lead for Renal Research. He is a member of the steering committee of BiCARB (funded by NIHR), the end point committee of PIVOTAL and in conjunction with colleagues in Dundee is running two British Heart Foundation funded clinical trials targeting cardiovascular risk in CKD.</p>

John McMurray		<p>John McMurray is a Professor of Medical Cardiology and Deputy-director (Clinical) of the Institute of Cardiovascular and Medical Sciences, at the University of Glasgow, and Honorary Consultant Cardiologist at the Queen Elizabeth University Hospital, Glasgow.</p> <p>His main research interests include heart failure and the cardiovascular consequences of diabetes and chronic kidney disease, with a focus on clinical trials. He has chaired and participated in numerous clinical trial executive/steering and data-monitoring committees. He leads the event adjudication group at Glasgow University, which has served as the endpoint committee for many trials.</p>
Shahid Muhammed		<p>Shahid is a Specialist Biomedical Scientist and member of the Healthcare Professions Council (HCPC). Shahid is a Fellow for the Institute of Biomedical Sciences (FIBMS) and a Chartered Scientist under the Science Council (CSci). Shahid is also a member for the British Blood Transfusion Society (BBTS). Shahid has built experience in laboratory and health research practices and his understanding surrounds the biomedical/clinical and social sciences. Shahid has provided multidisciplinary team working perspectives from laboratory to community and wider through several key publications. Shahid co-founded the Renal Patient Support Group (RPSG) in (2009) which is an evidence-based support group for patients and carers in Chronic Kidney Disease (CKD); the group now has a vast international membership. Shahid has presented work locally, regionally, in various European countries and internationally.</p>
Dorothea Nitsch		<p>Dr Dorothea Nitsch is a Professor in Clinical Epidemiology at the London School of Hygiene & Tropical Medicine (LSHTM) and an Honorary Consultant Nephrologist at the Royal Free London NHS Foundation Trust where she sees patients. She is the MSc Epidemiology Programme Director at LSHTM. Her research investigates the epidemiology of chronic kidney disease using a variety of methods including life-course epidemiology, genetic epidemiology, utilising big data, and pharmaco-epidemiology. She collaborates widely and has co-authored over 100 papers in peer-reviewed journals. She is the principal investigator of the MRC Older Age study which contributes data to the international</p>

		<p>Chronic kidney disease prognosis consortium. She leads the analyses of the National Chronic Kidney Disease Audit, which assesses the identification and management of people with kidney disease in English and Welsh primary care practices. She is a member of the UK Renal Association Research Committee and chairs the UK Renal Registry Research Methods Study Group.</p>
<p>Rukshana Shroff</p>		<p>Rukshana Shroff, MD, FRCPCH, PhD, is a Consultant in Paediatric Nephrology at Great Ormond Street Hospital for Children in London UK, and Reader at University College London. Her research focuses on cardiovascular disease in childhood chronic kidney disease (CKD), including laboratory work, clinical research studies and clinical trials. She is the PI on a multicentre study comparing long-term outcomes of conventional hemodialysis and hemodiafiltration in children. She currently holds a senior fellowship from the National Institute for Health Research (NIHR) to continue research into mineral dysregulation in CKD. She has been Chief Investigator for a number of multicentre clinical trials, and has supervised 9 MD / PhD fellows. She has published more than 130 original articles, reviews and book chapters in the fields of nephrology and dialysis. Dr Shroff has served on the recent KDIGO CKD-MBD guideline update group, a guideline development group with the International Society for Peritoneal Dialysis and two guideline committees for the National Institute for Health and Care Excellence (NICE). She is on the Council for the European Society for Pediatric Nephrology. She is currently an Associate Editor for Pediatric Nephrology and serves on the editorial board of the Clinical Journal of the American Society of Nephrology.</p>

James Wason		<p>James Wason is a Professor of Biostatistics at Newcastle University and a group leader at the MRC Biostatistics Unit, University of Cambridge. He leads a research group focused on development of statistical methods for more efficient trials. His research interests are adaptive designs, using biomarkers prospectively during trials and analysis of composite endpoints. As well as working on methodology, James is very interested in applying novel methods in real clinical trials and is currently involved in several ongoing trials using novel designs.</p>
David Wheeler		<p>David Wheeler is Professor of Kidney Medicine at University College London, UK and an Honorary Consultant Nephrologist at the Royal Free London NHS Foundation Trust. He is a clinician scientist with an interest in the complications of chronic kidney disease, specifically those that increase the burden of cardiovascular disease and/or accelerate progression of kidney failure. Professor Wheeler has participated in the design and running of several large-scale clinical trials including SHARP, EVOLVE and CREDENCE. He currently co-chairs the Steering Committee of the DAPA-CKD study. He leads the Clinical Research team at the UCL Centre for Nephrology and is Clinical Lead for Division 2 of the National Institute for Health Research North Thames Clinical Research Network. He has been involved in clinical practice guideline development for several organisations, most recently for Kidney Disease: Improving Global Outcomes (KDIGO), of which he is currently Co-Chair. A past President of the UK Renal Association and Chair of the UK Renal Registry, Professor Wheeler's other responsibilities include Editorial Board membership of the Journal of the American Society of Nephrology.</p>

<p>Claire White</p>	 A portrait photograph of Claire White, a woman with blonde hair, wearing a light-colored top, smiling slightly. The background is a plain wall with a framed picture partially visible.	<p>Claire White is a Pharmacist with experience of drug development, clinical research processes and delivery of clinical trials. Claire started her career in the pharmaceutical industry where she held various Research & Development positions working on Phase I -III clinical studies across a range of therapeutic areas. In 2009, Claire moved to the NHS sector and worked at East Kent Hospitals NHS Foundation Trust where she was responsible for managing the Clinical Trials Pharmacy Service as well as being the Trust representative on the CRN Regional Clinical Trials Pharmacy Group. Latterly, Claire worked at King's College Hospital and was the Clinical Trial Manager for the PIVOTAL Study. Claire currently works as a Clinical Scientist at Pfizer Ltd where she works on a number of clinical programmes, including an initiative which aims to improve the patient and study team experience in clinical trials.</p>
---------------------	---	---

November 2019